Covid Vaccine Race

The participant was taking a placebo and the trial will continue according to initial reports.

Many unknowns remain as the scientific community focuses on its goal of issuing a vaccine for COVID-19.

Covaxx has developed its investigational vaccine and is currently in a phase 1/2 trial.

Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.

Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.

The company made the announcement Monday night.

In consideration of the idea that the pandemic may lead to greater knowledge and adoption of preventive health measures.

Numerous candidates are in late-stage assessment. An expert shares what the diverse agents should show before being considered for regulation.

The new guidance bucks against the White House's campaign message of an available prophylaxis by the election.

Perspective on the ongoing independent safety reviews for one of the more promising vaccine candidates.

A discussion with an expert on the particularities of the vaccines, which vary in temperature climate requirements and dosages.

Why the AstraZeneca & Oxford University trial's pause due to an adverse event was a sign to Fauci the vaccine monitoring systems are working.

International collaboration, fast action, and mRNA platform technology led to phase 3 trials in record time—without compromise of safety standards.

The agency requested data this week, following the pause of large-scale international assessment after a non-fatal serious adverse event was reported in a UK participant earlier this month.

The country is split on certain strategies and a potential vaccine. Here's why the message needs to go from national to regional.

J&J is evaluating both 1- and 2-dose regimens of the adenovirus vector investigational vaccine.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

What we've seen non-immunized communities do for previously eradicated outbreaks.

The logistics of supplying the vaccine are being handled by a collaboration of federal agencies. The DoD, parts of HHS, and CDC are coordinating supply, production, and distribution.

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

Results of the trial of Novavax’s NVX-CoV2373 vaccine have been published in the New England Journal of Medicine, showing the vaccine appeared safe and elicited strong immune responses.

A new report shows a UK-based participant experienced a serious adverse event, but is anticipated to recover.

If phase 1/2 data is positive, the companies plan to move into phase 3 by December.

The federal agency sent a checklist and priority list to all 50 states and 5 large American cities as it prepares for vaccine approval.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

The company is recruiting up to 30000 Americans for AZD1222, its vaccine candidate, as it enters a late-stage trial.